Return to homepagePandemic Pact

Harnessing optimal anti-viral CD8+ T cell immunity for high-risk populations

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA352266

Grant search

Key facts

  • Disease

    COVID-19, Unspecified

  • Start & end year

    2024
    2028

  • Known Financial Commitments (USD)

    $453,114.21

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    University of Melbourne

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Killer T cells recognise short protein fragments (peptides) derived from viruses and presented on the surface of virus-infected cells. I will investigate killer T cells that recognise specific fragments from influenza viruses and SARS-CoV-2, and their ability to provide long-lasting immunity and hence protection against future infections in high-risk populations. This knowledge will be used in vaccine strategies aimed at providing universal immunity to influenza strains & SARS-CoV-2 variants.